Dafinchi AI

Bio-Techne Corporation

TECH

Healthcare

1w

Strategic divestiture of Exosome Diagnostics to MDxHealth

Bio-Techne announced the divestiture of Exosome Diagnostics, including the ExoDx prostate test and clinical lab to MDxHealth.
Expected close in the first quarter of fiscal 2026.
Retains access to proprietary exosome technology used in ESR1 mutation kit for breast cancer recurrence.
Repositioning of portfolio to focus on core growth pillars and improve operating margin.

Exact Sciences Corporation

EXAS

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA reached an all-time high of $138 million, a 26% increase, with margin expansion of 130 basis points due to pricing and productivity gains.
Cash and marketable securities ended at $858 million.
Exact Sciences delivered a record 1.3 million test results in Q2 2025, with core revenue growth accelerating to 16% year-over-year.
Free cash flow was $47 million in Q2, with year-to-date free cash flow increasing by $95 million compared to the prior year.
GAAP net income was negative $1 million, including $15 million in one-time operational efficiency costs.
Precision oncology revenue grew 9% to $179 million on a core basis, supported by Oncotype DX international adoption and sublicensing revenue from TwinStrand technology.
Screening revenue increased 18% to $628 million, driven by Cologuard rescreens, care gap programs, and improved commercial execution.

Exact Sciences Corporation

EXAS

Healthcare

1w

Freenome Blood-Based CRC Test Licensing and Strategic Implications

Exact Sciences licensed exclusive rights to Freenome's blood-based colorectal cancer screening tests, including current and future versions, subject to regulatory approval.
The licensing agreement allows for potential deployment of improved next-generation blood tests, with the possibility to exit if performance thresholds are not met.
Management views the Freenome technology as a strategic addition that accelerates time to market and broadens the company's portfolio beyond stool-based tests.
The company emphasizes the importance of the blood test in reaching patients who refuse traditional screening methods, targeting a niche market with high unmet need.
Freenome's initial test showed 73% sensitivity for colon cancer, but management expressed disappointment with the results, indicating ongoing internal testing and evaluation.
The agreement includes a flexible structure with a 10% royalty, providing strategic optionality without full acquisition, balancing risk and investment.

EXEL

Healthcare

3w

Strong U.S. Cabozantinib Franchise Growth and Net Launch Momentum

U.S. cabozantinib net product revenues increased 19% YoY to $520 million in Q2 2025.
Growth driven solely by commercial demand with negligible clinical trial sales and gross-to-net headwinds.
Rapid uptake in new indications, including neuroendocrine tumors (NET), contributing approximately 4% of total revenue.
Leading market share in second-line plus NET segment with about 35% new patient share in Q2 2025.
European approval for NET indication received by partner Ipsen, expanding royalty streams.
Continued evaluation of revenue guidance as momentum builds in net launch and additional revenue opportunities.

Incyte Corporation

INCY

Healthcare

2w

Strategic Focus on Myeloproliferative Neoplasms (MPNs) as Incyte's Primary Priority

Incyte's leadership emphasizes MPNs as the company's most important therapeutic area, with a potential to transform treatment standards.
The company aims to dominate the MPN space with targeted therapies like 989 and 617, aiming to set a new high watermark in treatment.
Progress with 989 shows promising safety and efficacy, with plans to initiate pivotal trials in ET by early 2026.
The strategic focus on MPNs is driven by the company's asymmetrical advantage and the potential to create a series of innovations in this space.

Waters Corporation

WAT

Healthcare

2w

Waters' Strategic Growth and Innovation Initiatives in 2025

Sales grew 9% in Q2, driven by revitalized innovation and expansion into high-growth areas.
Key product launches like Alliance iS (300% growth YoY), Xevo TQ Absolute (40% growth), and MaxPeak columns (30% growth) are gaining market traction.
Introduction of BioResolve Protein A Affinity Columns marks entry into bioseparations, expanding product portfolio.

McKesson Corporation

MCK

Healthcare

1w

McKesson's Strategic Focus on Oncology and Biopharma Expansion

Acquisition of controlling interest in Core Ventures, expanding access to cancer care in local communities.
Growth of U.S. Oncology Network to approximately 3,300 providers across 700 sites in 30 states.
Expansion into other therapeutic areas like ophthalmology with PRISM Vision acquisition.
Leverage of oncology platform to generate data insights and accelerate growth.

Bristol-Myers Squibb Company

BMY

Healthcare

2w

Strategic Partnership with BioNTech for PD-L1 VEGF Bispecific BNT327

BMS entered into a global strategic partnership with BioNTech to co-develop and commercialize BNT327, a potentially transformative PD-L1 VEGF bispecific therapy.
The collaboration aims to accelerate clinical trials, expedite time to market, and expand indications, with the goal of positioning BNT327 as a first or second to market in its class.
The partnership leverages BMS' expertise in immuno-oncology and BioNTech's innovation, with a focus on speed to market and broadening indications.
Initial clinical development is underway in small cell lung cancer, non-small cell lung cancer, and triple-negative breast cancer.

OraSure Technologies, Inc.

OSUR

Healthcare

1w

Progress on Strategic Pillars and Innovation Roadmap

OTI is advancing its strategic transformation focusing on strengthening foundation, elevating core growth, and accelerating profitable growth.
Reported revenue in Q2 was in the top half of guidance range.
Launched HEMAcollect PROTEIN in July to expand into proteomic research and blood sample management.
Progress on innovation includes new product launches and expanding client relationships.
Management emphasizes disciplined execution and long-term value creation.

NeoGenomics, Inc.

NEO

Healthcare

2w

Financial Performance Summary

Adjusted EBITDA was $10.7 million, down 2% from prior year, impacted by Pathline acquisition ramp; excluding Pathline, adjusted EBITDA grew 13%.
Adjusted gross profit improved by $4.6 million or 6% over prior year.
Cash flow from operations was positive $20 million, up 44% year-over-year, with cash and marketable securities ending at $164 million.
Clinical revenue grew 16% year-over-year with organic clinical revenue up 13%, driven by a 10% increase in test volumes and a 3% increase in average unit price (AUP).
NeoGenomics reported Q2 2025 revenue of $181 million, representing 10% year-over-year growth but slightly below guidance.
NGS testing accounted for 32% of total clinical revenue and grew 23%, slightly below the 25% target but above market growth rates.
Nonclinical revenue declined 26% year-over-year due to weakness in pharma and biotech customer demand.
The company retired $201 million of convertible notes in Q2, significantly reducing debt.

Coherus BioSciences, Inc.

CHRS

Healthcare

1w

Strategic Repositioning and Company Rebranding to Coherus Oncology

The company completed a strategic repositioning in Q2 2025, including a rebranding to Coherus Oncology to better reflect its mission.
Leadership emphasized the importance of aligning the company's identity with its focus on innovative cancer therapies.
The rebranding aims to enhance market perception and better communicate the company's scientific and clinical ambitions.